Akoya Biosciences, Inc.’s AKYA share price has dipped by 5.46%, which has investors questioning if this is right time to buy.

Piper Sandler analyst David Westenberg lowered the firm’s price target on Akoya Biosciences (AKYA) to $1.65 from $2.40 and keeps a Neutral ...

Kent Lake PR LLC ("Kent Lake"), a holder of approximately 7.7% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ: QTRX), today announced that it has filed ...

Piper Sandler analyst David Westenberg maintained a Hold rating on Akoya Biosciences (AKYA – Research Report) today and set a price target of ...

Akoya Biosciences (NASDAQ:AKYA – Get Free Report)‘s stock had its “overweight” rating reaffirmed by equities researchers at Stephens in a research note issued on Tuesday,Benzinga reports.

QTRX), today issued a statement calling on the Company to explain its most recent purchase agreement for up to $30 million in convertible notes from Akoya Biosciences, Inc. ("Akoya") (Nasdaq ...

(Bloomberg) -- Quanterix Corp. is in advanced talks to acquire life sciences peer Akoya Biosciences Inc. in an all-stock deal, according to people familiar with the matter, potentially combining ...

Akoya Biosciences had a negative return on equity of 162.99% and a negative net margin of 66.77%. The company had revenue of $21.34 million for the quarter, compared to the consensus estimate of ...

Akoya’s technology to generate data for a first-of-its-kind Biobank and Data Repository for Cancer Equity Research, funded through the Cancer Grand Challengesinitiative The unprecedented scale ...

(“Quanterix” or the “Company”), today announced that it intends to vote AGAINST the Company’s proposed merger with Akoya Biosciences, Inc. (“Akoya”) (Nasdaq: AKYA) at the upcoming ...

QTRX), today issued a presentation to Quanterix shareholders in connection to Kent Lake’s opposition to the Company’s proposed transaction (the “Transaction”) with Akoya Biosciences ...